Site Search

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.

The number of state privacy and AI laws are rapidly increasing– and regulators are no longer just watching. From million-dollar CCPA settlements to Attorney General enforcement sweeps, the cost of non-compliance is real, and it is growing.

This session cuts through the complexity of today's overlapping state privacy and AI legal landscape and delivers a practical, step-by-step compliance roadmap that organizations can actually implement. 

Microplastics are plastic particles found across the environment—in water supplies, food sources, and human tissue—and have emerged as a frontline legal and regulatory issue. The science is developing quickly, and regulatory and litigation activity is following close behind, from EPA's inclusion of microplastics on its draft Sixth Contaminant Candidate List (CCL 6) as a priority contaminant group to growing state legislation and an expanding wave of private litigation. Companies across industries are facing increasing uncertainty and risk.